201. Effect of Dapagliflozin Treatment on the Expression of Renal Sodium Transporters/Channels on High-Fat Diet Diabetic Mice
- Author
-
Jeroen H. F. de Baaij, Bastiaan E. de Galan, Victor A. Gault, Chao Ma, Joost G. J. Hoenderop, René J. M. Bindels, and Paul Millar
- Subjects
Blood Glucose ,Male ,medicine.medical_specialty ,Antiporter ,030232 urology & nephrology ,Nephron ,030204 cardiovascular system & hematology ,Diet, High-Fat ,Streptozocin ,Diabetes Mellitus, Experimental ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Glucosides ,Experimental Nephrology and Genetics: Original Paper ,Internal medicine ,Diabetes mellitus ,medicine ,Animals ,Distal convoluted tubule ,Dapagliflozin ,Benzhydryl Compounds ,Sodium-Glucose Transporter 2 Inhibitors ,business.industry ,Body Weight ,Sodium ,Membrane Transport Proteins ,Metabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6] ,medicine.disease ,Streptozotocin ,medicine.anatomical_structure ,Endocrinology ,Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11] ,chemistry ,Ascending limb of loop of Henle ,Sodium-Potassium-Exchanging ATPase ,business ,Cotransporter ,medicine.drug - Abstract
Background: Inhibition of the Na+/glucose co-transporter 2 is a new therapeutic strategy for diabetes. It is unclear how proximal loss of Na+ (and glucose) affects the subsequent Na+ transporters in the proximal tubule (PT), thick ascending limb of loop of Henle (TAL), distal convoluted tubule (DCT) and collecting duct (CD). Methods: Mice on a high fat diet were administered 3 doses streptozotocin 6 days prior to oral dapagliflozin administration or vehicle for 18 days. A control group of lean mice were also included. Body weight and glucose were recorded at regular intervals during treatment. Renal Na+ transporters expression in nephron segments were analyzed by RT-qPCR and Western blot. Results: Dapagliflozin treatment resulted in a significant reduction in body weight and blood glucose compared to vehicle-treated controls. mRNA results showed that Na+-hydrogen antiporter 3 (NHE3), Na+/phosphate cotransporter (NaPi-2a) and epithelial Na+ channel expression was increased, Ncx1, ENaCβ and ENaCγ expression declined (p all < 0.05), respectively, in dapagliflozin-treated mice when compared with saline vehicle mice. Na-K-2Cl cotransporters and Na-Cl cotransporter mRNA expression was not affected by dapagliflozin treatment. Na+/K+-ATPase (Atp1b1) expression was also increased significantly by dapagliflozin treatment, but it did not affect Atp1a1 and glucose transporter 2 expression. Western blot analysis showed that NaPi-2a, NHE3 and ATP1b1 expression was upregulated in dapagliflozin-treated diabetic mice when compared with saline vehicle mice (p < 0.05). Conclusion: Our findings suggest that dapagliflozin treatment augments compensatory changes in the renal PT in diabetic mice.
- Published
- 2019